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3-kinase; STAT-3 = signal transducer and activator of transcription-3; TEB = terminal end bud.
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Introduction
The insulin-like growth factors (IGF)-I and -II are single-
chain polypeptides that share 62% homology in their
amino acid sequences. Although at least two receptors for
IGFs exist, the primary signalling receptor through which
both IGF-I and IGF-II exert their biological actions is the
type I insulin-like growth factor receptor (IGF-IR). The IGF-
IR binds IGF-I and IGF-II with high affinity (Kd ~1–2 nM)
and binds insulin with an affinity that is 500–1000 times
lower. IGFs can also bind and activate the insulin receptor
[1]. IGFs are synthesized and secreted by many tissues,
and they can act locally as autocrine or paracrine factors,
or as endocrine factors that circulate in the plasma.
IGFs have both immediate and long-term effects on
various cellular activities. For example, IGF-I exerts an
acute anabolic action on protein and carbohydrate meta-
bolism by increasing the cellular uptake of amino acids
and glucose by stimulating glycogen and protein synthesis
[2]. IGFs also have long-term impact on cell proliferation,
differentiation, migration and survival (for general reviews
on IGF function, see [3,4]).
The actions of IGFs can be modulated by interaction with a
family of six insulin-like growth factor-binding proteins
(IGFBPs), IGFBP-1 to IGFBP-6, which share 40–60%
amino acid identity. All six IGFBPs have 16–18 conserved
cysteine residues in the amino and carboxy terminal
regions. The majority of circulating IGFs (>97%) are
bound to IGFBPs, particularly to IGFBP-3, with an affinity
equal to or greater than that of the IGF-IR [5]. By binding
IGF-I and IGF-II, IGFBPs regulate the bioavailability of IGFs
in the circulation; however, their functions at the cellular
level are not fully understood. IGFBPs have been reported
to both inhibit and enhance IGF-I action depending on the
system under investigation and the IGFBP studied.
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In common with IGFs, IGFBPs have complex patterns of
expression and physiological regulation both during
embryogenesis and in the adult, and they play an impor-
tant role in the development and function of a number of
key systems. The present review will discuss the function
of IGFs and their binding proteins in the normal mammary
gland, and will consider their role in breast cancer.
Regulation and expression of IGFs in the
mammary gland
The hormonal control of mammary gland development is
complex and involves ovarian, adrenal and pituitary hor-
mones. One such pituitary hormone, growth hormone
(GH), is essential for mammary gland development
because mice lacking the growth hormone receptor
(GHR) have a severely compromised ductal network [6].
IGF-I is the primary mediator of the actions of GH, since
mammary ductal development is considerably diminished
in hypophysectomized rats and can be restored by
mammary implants containing IGF-I [7,8].
Although GH regulates IGF-I production from the liver,
which is the major circulating source of IGFs, it can also
modulate locally produced IGFs. Indeed, treatment of
mammary tissue with GH induces a dose-dependent
increase in IGF-I mRNA in organ culture [8,9], consistent
with a key role for locally produced IGFs, under the control
of systemic hormones.
IGFs are synthesized by stromal cells of the mammary
connective tissue (i.e. fibroblasts and adipocytes). This
supports the well-known concept that stromal–epithelial
interactions are vital for full mammary gland development.
IGF-I and IGF-II mRNA are thus expressed in stromal cells,
while the IGF-IR is present within the epithelium [10]. The
GHR is also present in stroma, and tissue recombination
experiments indicate that GHR expression by stromal
cells, rather than the epithelium, is essential for mammary
development [6]. Moreover, GH induces IGF-I mRNA in
isolated epithelium-free mammary stroma [8]. It thus
appears that GH activates the GHR within stromal fibro-
blasts and/or adipocytes, thereby inducing expression of
IGF-I, which then acts on the IGF-IR in the epithelium
(Fig. 1). Interestingly, a comparison of IGF-I mRNA expres-
sion in mammary fat pads with and without glandular
epithelium revealed higher stromal expression when the
epithelium is present [11]. This suggests the involvement
of reciprocal interactions whereby the epithelial cells feed-
back on the stromal cells to modulate production. One
further issue of note is the lack of studies on the effect of
IGFs on mammary stromal cells. Since IGF-I is important
in regulating adipocyte differentiation in cultured cells
[12], this is an area that may deserve future attention.
In addition to the expression of IGFs in stroma, mRNA has
also been detected within the epithelial compartment of
the mammary gland, particularly during ductal develop-
ment [13]. IGFs are strongly expressed in terminal end
buds (TEBs), which are the main proliferative units of the
pubertal developing gland [9]. Interestingly, IGF-II mRNA
appears in sporadic epithelial cells within the ducts and
alveoli of the pregnant gland [13]. The mechanism respon-
sible for initiation of expression of IGFs in the epithelium
has not been identified, but it may be through oestrogen,
which causes a twofold to threefold increase in the
expression of IGF-I mRNA in human breast tissue
implanted as xenografts in nu/nu mice [14]. Given that the
oestrogen receptor (ER) is mainly expressed within the
mammary epithelium but not in the cells that undergo DNA
synthesis [15], it is possible that oestrogen induces the
epithelial expression of IGFs, which then mediates a
paracrine growth signal for neighbouring epithelial cells
(Fig. 1). Whether these paracrine mechanisms involving
IGF-I produced within the stroma and the epithelium are
the major driving force for proliferation in the mammary
gland has not yet been fully explored. However, other
locally produced growth factors (e.g. RANK ligand) are
also essential at specific times of development such as
during alveolargenesis [16].
The actions of IGFs within the mammary
gland
Activation of the IGF-IR occurs following IGF-I binding to
the α-subunit of the IGF-IR on epithelial cells, leading to
autophosphorylation of the β-subunit by an intrinsic tyro-
sine kinase. These events can lead to the activation of a
number of downstream pathways including the insulin-
receptor substrate/phosphatidylinositol 3-kinase (PI3K)/
protein kinase B pathway and the Ras/Raf/mitogen-
activated protein kinase (MAPK) pathway (for a review on
mechanisms of IGF signalling, see [17]). IGFs play a key
role in proliferation and survival in the mammary gland, par-
ticularly during puberty and pregnancy. It has been sug-
gested that the MAPK pathway drives the cell proliferative
response whereas the PI3K pathway is required for sur-
vival effects [18], but it is probable that the cellular
response depends on the concentration and the time
course. Additionally, crosstalk between these pathways
has been demonstrated in the human breast cancer cell
line MCF-7 [19].
IGF-mediated proliferation
Proliferation occurs during the two major stages of
mammary gland development. During puberty, there is
extensive ductal lengthening through proliferation of cells
in the TEBs located at the tips of the epithelial ducts
accompanied by side branching of mature ducts. During
pregnancy, the gland continues to proliferate and differen-
tiate, with the formation of secretory alveoli in preparation
for lactation. Evidence for an essential role of IGFs in
mammary epithelial cell proliferation is provided by both
culture and animal models.233
IGF-I maintains the growth of normal mammary epithelial
cells in culture [20,21]. It is a potent mitogen for mammary
epithelial cells and, in combination with mammogenic hor-
mones, IGF-I induces ductal growth in mammary gland
explant cultures [13]. IGF-I null mice have deficient
mammary development with reductions in the number of
TEBs, ducts and the per cent of the fat pad occupied by
glandular elements [9]. This phenotype is partially restored
by administration of des(1–3)IGF-I [9]. Results gained
from transplantation studies indicate there is also a signifi-
cant reduction of cell proliferation within the TEBs of the
IGF-IR null pubertal mammary gland, accompanied by a
decrease in the size and number of the TEBs, and by con-
siderably diminished ductal network and associated
branching [22]. Interestingly, the loss of ductal develop-
ment in the IGF-IR null mammary gland is largely reversed
during pregnancy, suggesting the activation of compen-
satory pathways for proliferation.
IGF-mediated survival
IGFs now appear to be one of the essential survival
factors for the mammary epithelium, although other factors
such as epidermal growth factor (EGF) and its homo-
logues also deliver intracellular signals that suppress
apoptosis [23]. Direct evidence for IGFs as survival
factors comes from culture studies. IGF-I or IGF-II can
suppress the apoptosis of mammary epithelial cells
induced by serum withdrawal [24]. It has recently been
established that this is achieved through PI3K and MAPK
signals that ultimately inhibit the activity of the proapop-
totic protein BAD [23].
During pregnancy, there is inhibition of epithelial apoptosis
by survival factors. Following lactation and weaning,
however, involution occurs in which survival signals are
removed/neutralized and the alveolar epithelial cells die by
apoptosis [25–27]. Evidence for the role of IGFs in this
process has been gained from transgenic mouse models.
Involution is delayed in mice overexpressing human IGF-I
or des(1–3)IGF-I due to reduced alveolar apoptosis
[28,29]. Similarly, apoptosis is reduced, functionally intact
lobuloalveolar alveoli persist and involution is delayed in
IGF-II-overexpressing mice [30]. The mechanism for IGF-
mediated mammary cell survival in vivo has not been
established, but it may involve components of the PI3K
signalling pathway, as mice expressing an activated form
of protein kinase B, which acts downstream of PI3K, show
extensively delayed involution [31,32]. Since protein
kinase B can integrate a variety of survival signals,
however, it is now important to determine whether geneti-
cally altered mice with absent or mutated proximal compo-
nents within the IGF signalling axis have defective
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Figure 1
Insulin-like growth factor-I (IGF-I) signalling networks in the mammary gland. Growth hormone (GH) acting on the growth hormone receptor (GHR)
on stromal cells induces IGF-I release, which subsequently acts at the type I insulin-like growth factor receptor (IGF-IR) on epithelial cells to
mediate survival and proliferation. Oestrogen can also induce IGF-I expression, which may then act on adjacent mammary epithelial cells. The
basement membrane provides an interface between stroma and epithelial cells, and it can contribute to the signals required for mammary
development via integrin receptors. Epidermal growth factor (EGF) can synergize with IGF-I, and IGF-I can transactivate the EGF receptor (EGFR).
ER, oestrogen receptor.
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mammary apoptosis in vivo, but such studies have not yet
been performed.
Crosstalk between IGFs and other factors
Although IGFs drive specific intracellular signalling path-
ways that are involved with epithelial cell proliferation and
survival, their ability to regulate the cell phenotype is
dependent on crosstalk with other molecules within the
mammary gland.
IGF-I synergizes with oestrogen in TEB formation [33],
and the combination can stimulate ductal morphogenesis
in IGF-I null mice [9]. One possibility is that oestrogen
activates the IGF-IR, as occurs in the uterus [34,35].
However, most of the work to elucidate the mechanism of
crosstalk has been gained using breast cancer cell lines.
The interaction between IGFs and oestrogens will there-
fore be explored further in the context of mammary gland
malignancy (see “IGF axis and oestrogen in breast
cancer” section below).
IGFs also cooperate with EGF to increase mammary
epithelial cell proliferation. Whereas IGF-I and EGF can
induce expression of early G1-type cyclins in cultured
mammary cells, IGF-I is specifically required to traverse
the G1–S checkpoint [36]. The EGF receptor can act as a
nodal point for interception of several classes of signal,
including G-protein-coupled receptors and integrins
[37,38], and can also be activated indirectly by IGF-I [23].
Indeed, IGF-I partially mediates its survival effect on
mammary epithelial cells through transactivation of the
EGF receptor and the consequent stimulation of MAPK
[23] (Fig. 1).
The extracellular matrix (ECM), particularly the specialized
matrix known as the basement membrane, plays a key and
direct role in mammary epithelial physiology [39,40]. The
basement membrane surrounds the mammary ducts and
alveoli, and it contains laminin, nidogen, heparan sulphate
proteoglycan and collagen IV [27]. Not only does the
basement membrane provide a structural interface
between the mammary stroma and the epithelium (Fig. 1),
it also contributes to proliferation, survival and differentia-
tion of mammary epithelial cells by signalling through inte-
grin receptors [41]. For example, activation of
insulin-receptor substrate-1 (IRS-1) and PI3K by insulin, at
supraphysiological concentrations that bind the IGF-IR,
occurs to a greater extent when mammary epithelial cells
are cultured on basement membrane compared with colla-
gen I [24].
The mechanism for ECM-dependent control of IGF sig-
nalling has not been elucidated, but it may involve direct
interactions between integrins and components of the IGF
signalling pathways as occurs in other cell systems [42]
or, alternatively, adhesion-regulated control of IGF
signalling through protein tyrosine phosphatases [43].
Interestingly, IGF-IR binding is significantly increased
when primary cultures of mammary epithelial cells are
plated on laminin compared with other substrata such as
collagen type I, collagen type IV and fibronectin [44]. The
synergistic proliferative response between IGF-I and EGF
is also more marked when cells are grown on laminin, in
comparison with the nonspecific attachment factor poly-L-
lysine. In addition to the involvement of ECM adhesion in
regulating IGF signalling, integrins directly activate IRS-I in
breast cancer cells, further substantiating the idea that
adhesion and IGF signalling networks cooperate with
each other [45].
Together, these observations indicate that a more complex
model for IGF signalling exists, rather than the conven-
tional model involving linear pathways through MAPK and
PI3K. Indeed, IGF signalling should now be thought of as
just one component in a complex network of signals where
a variety of extracellular inputs become integrated within
the cell to produce multiple, yet carefully orchestrated, sig-
nalling outputs for controlling the balance between prolif-
eration and survival.
IGFBP expression in the mammary gland
In addition to crosstalk with other hormones, growth
factors and the ECM, IGFs are also regulated by associa-
tion with IGFBPs. In comparison with IGFs, less is known
about the function of IGFBPs in the normal mammary
gland. The expression pattern of IGFBP mRNA in mice
has been determined during ductal and alveolar develop-
ment [46]. All six mRNAs are present in the TEBs of the
pubertal virgin gland, with IGFBP-3 and IGFBP-5 appear-
ing most prominently. IGFBP-5 mRNA is present through-
out the TEB, but IGFBP-3 mRNA is expressed in cells
along the outer edge of the TEB in a pattern correspond-
ing to cap cells, the putative stem cells of the mammary
gland. IGFBP-3 mRNA and IGFBP-5 mRNA are also
highly expressed in the stroma, in addition to the ductal
and alveolar epithelium in the pregnant gland. In the preg-
nant gland, IGFBP-2 mRNA, IGFBP-4 mRNA and IGFBP-
6 mRNA can be detected but this is restricted to the
stroma [46].
IGFBPs as regulators of IGF-mediated effects
Since IGFBPs have an equal or greater affinity for IGFs
compared with the affinity of the IGF-IR, the presence of
IGFBPs could inhibit IGF activity by decreasing levels of
free IGFs available to activate the receptor (Fig. 2). Such a
mechanism has been proposed based on a study examin-
ing the expression of IGFBPs in rat milk during involution.
A dramatic increase in the concentration of IGFBP-5 is
observed in rat milk 48 hours after the removal of the suck-
ling young [47]. A similar change in the mRNA level
occurs at this time, indicating that the IGFBP-5 present in
rat milk is derived from the gland and does not enter by
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translocation from the circulation. Consistent with this, the
most abundant IGFBP in the mouse mammary gland is
IGFBP-5, expression of which is low during pregnancy
and lactation but dramatically increases at involution
(unpublished observations). This suggests that IGFBPs
act locally within the mammary gland in close proximity to
the cells involved in IGFBP production. It has thus been
proposed that the presence of IGFBP-5 at involution
inhibits the survival function of IGFs, leading to apoptosis.
One possible mechanism to explain the increased levels of
IGFBP-5 after weaning is that prolactin withdrawal results
in IGFBP-5 synthesis. Evidence for this is provided by
treating rats with prolactin at the same time as pup
removal, resulting in a 90% inhibition of IGFBP-5 appear-
ance in milk [47]. Prolactin may regulate IGFBP-5 expres-
sion indirectly through interferon regulatory factor-1
(IRF-1), since mice lacking IRF-1 in the mammary gland
have increased IGFBP-5 expression and accelerated invo-
lution [48]. An alternative possibility is that IGFBP-5
expression is induced by a cytokine that activates the
signal transducer and activator of transcription-3 (STAT-
3). Pup removal in wild-type mice dramatically activates
STAT-3, an event that is functionally linked to mammary
apoptosis since mice lacking STAT-3 in their mammary
glands have both delayed involution and a reduced upreg-
ulation of IGFBP-5 [49].
A model thus emerges where, during pregnancy and lacta-
tion, GH increases IGF-I synthesis and prolactin represses
IGFBP-5 synthesis to maximize the survival and prolifera-
tive effects of IGF-I. Following weaning, however, the loss
of prolactin and concomitant downregulation of IRF-1,
together with the upregulation of a cytokine that activates
STAT-3, leads to IGFBP-5 expression, thereby inhibiting
IGF survival signalling and inducing mammary epithelial
apoptosis. Although important, the IGF axis does not act
alone in regulating mammary involution, as studies with
genetically altered mice indicate an essential role for both
the proapoptotic factor transforming growth factor β3 [50]
and the survival factor tissue inhibitor of metallopro-
teinase-3 [51].
Even though IGFBP-5 probably has a role in the initiation
of apoptosis at involution in rodents, other IGFBPs may
play a similar role in humans. IGFBP-2 is the major IGFBP
in human milk, while IGFBP-1 and IGFBP-3 are present at
lower concentrations and IGFBP-5 has not been detected
[52,53]. Additionally, IGFBP-3 but not IGFBP-5 induces a
number of cellular effects in human breast cancer cell
lines [54,55]. For example, exogenous IGFBP-3 but not
IGFBP-5 inhibits IGF-IR activation and blocks phosphory-
lation of IRS-1 in MCF-7 cells [55]. In contrast to these
studies that suggest a role for IGFBP-3 in inhibiting IGF-
mediated effects in the human mammary gland, evidence
from transgenic mice overexpressing IGFBP-3 indicates
that IGFBP-3 may have a prosurvival function [28]. The
physiological significance of this is not clear given that
endogenous levels of IGFBP-3 are low or undetectable in
the mouse mammary gland [47].
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Figure 2
The interplay between insulin-like growth factor (IGF) and insulin-like growth factor binding proteins (IGFBPs). Interactions between IGF and
IGFBPs can reduce free IGF levels, decreasing insulin-like growth factor receptor (IGF-IR) activation and inhibiting cellular response. Associations
of IGFBPs with extracellular matrix (ECM) components can reduce the affinity of IGFBP for IGFs, thereby releasing bioactive IGF. The actions of
proteases can also increase free IGF levels, since IGFBP fragments have reduced affinity for IGFs. IGFBPs may have direct effects mediated by as
yet uncharacterized IGFBP receptors.
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IGF-independent actions of IGFBPs
There is evidence that IGFBPs can regulate apoptosis not
only via sequestration of IGFs, but independently of IGFs.
In some cell systems, IGFBPs can induce apoptosis; for
example, IGFBP-3 induces apoptosis in MCF-7 breast
cancer cells [56]. This is not seen in other culture studies,
however, indicating that the effects of IGFBPs depend on
the cell type, the concentration and the time course of
exposure. IGFBPs may also regulate the effects of differ-
ent apoptotic stimuli. For example, IGFBP-3 does not
induce apoptosis alone but accentuates ceramide-
induced and UV-induced apoptosis in Hs578T breast
cancer cells [54]. In contrast, IGFBP-4 and IGFBP-5
inhibit ceramide-induced apoptosis in these cells. Hs578T
cells lack a functional IGF-IR, indicating that the effects of
IGFBPs are independent of IGF-I and could be mediated
by an additional receptor (Fig. 2). Cell-surface IGFBP-3
binding proteins of 20–50 kDa are present in Hs578T
cells but this putative receptor has not been fully charac-
terized [57]. IGFBP-3 and IGFBP-5 are also ligands for
the type V transforming growth factor β receptor [58].
Interestingly, IGFBP-3 and IGFBP-5 have nuclear localiza-
tion sequences and are found in the nucleus of T47D
human breast cancer cells, which may indicate an intracel-
lular role for IGFBPs [59].
IGFBP regulation by the ECM and matrix
metalloproteinases
IGFBPs interact with components of the ECM (Fig. 2). In
this way, free IGFs can be released from the circulating
IGF–IGFBP complex since ECM-associated IGFBPs have
a lower affinity for IGFs. For example, IGFBP-5 binds to
type III and type IV collagen, laminin and fibronectin, result-
ing in an eightfold reduction in its affinity for IGF-I [60,61].
Given the importance of the ECM in regulating growth
factor signalling, it is possible that ECM–IGFBP interac-
tions influence mammary function. However, there is cur-
rently little evidence to support this hypothesis.
The association of IGFBPs with the ECM also appears to
reduce the sensitivity of IGFBPs to proteolysis. Proteolysis
of IGFBPs results in the release of IGFs to receptors
since the majority of IGFBP fragments have reduced affin-
ity for IGFs (Fig. 2). A number of IGFBP proteases have
been identified including serine proteases such as
prostate-specific antigen, matrix metalloproteases includ-
ing MMP-2 and MMP-9, and the disintegrin metallopro-
tease ADAM 12 [62–65]. Other proteolytic enzymes that
are able to hydrolyse IGFBPs include plasmin, thrombin
and pregnancy-associated protein A [66–68]. Proteases
have a defined role in the mammary gland since cleavage
of the ECM and other proteins is required for TEB invasion
and side branching. Additionally, after about 3 days of
involution in the rodent gland, protease-mediated base-
ment membrane degradation occurs due to increased
activity of matrix metalloproteases and serine proteases to
remodel the mammary gland back to the primary ductal
structure [69]. The presence of specific IGFBP proteases
in the mammary gland has not been fully determined, and
further experimentation is now required to determine how
proteolysis regulates IGFBP, and therefore IGF, activity in
mammary development.
IGFs and IGFBPs in breast cancer
The mitogenic and survival function of IGFs is observed
not only in normal mammary cells, but also in breast
cancer cells. IGF-II mRNA and protein are more frequently
detected in primary tumours and human breast cancer cell
lines than IGF-I [70]. In addition, clinical studies show that
stromal cells surrounding the normal breast epithelium
secrete IGF-I while those surrounding the malignant
epithelium secrete IGF-II, suggesting that transformation
of breast epithelial cells may be associated with a switch
from stromal IGF-I to IGF-II expression [71,72]. Addition-
ally, the IGF-IR is overexpressed and highly activated in
breast cancer tissue compared with normal or benign
tissue [73,74]. Aspects of IGF-IR signal transduction and
its relevance in breast cancer have been reviewed exten-
sively [75].
Endocrine sources of IGF-I may also have a role in breast
cancer. In some studies, circulating IGF-I levels are higher
in breast cancer patients compared with normal controls
[76], and high IGF levels are associated with an increased
risk of breast cancer in premenopausal women [77]. In
another study, however, serum IGF-I levels were not asso-
ciated with overall 2-year survival [78].
A further factor associated with increased breast cancer
risk is the ratio between IGF-I and IGFBP-3 levels. Ele-
vated IGF-I and decreased IGFBP-3 levels are observed in
the serum of women presenting with stage I or stage II
breast cancer [79], and they correlate with an increased
risk of premenopausal ductal carcinoma in situ [80]. In
contrast to the reduction of IGFBP-3 in serum, IGFBP-3 is
three times more prevalent within tumours showing poor
prognostic features compared with those tumours with
good prognostic characteristics [81]. These conflicting
data may represent the different modes of actions of
endocrine versus locally produced IGFBPs.
IGF axis and oestrogen in breast cancer
The synergistic effect between IGFs and oestrogens is of
particular importance to breast cancer since the ER is a
strong prognostic factor for breast cancer growth. In
breast cancer cells, oestrogens enhance the mitogenic
effect of IGFs by inducing expression of several members
of the IGF family, including IGF-I and IGF-II, IGF-IR, IRS-1
and insulin-receptor substrate-2 [14,33,82–84]. The
increased expression of the IGF-IR and IRS-1 results in an
enhanced response to IGF-I, leading to increased MAPK
activation and therefore to proliferation. Conversely,
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removal of oestrogen results in a dramatic decrease in
IRS-1 expression and MAPK activity [83]. The interplay
between IGFs and oestrogens is reciprocal since IGF-I
can enhance expression of the ER in breast cancer [85].
In culture studies, ER-positive breast cancer cells such as
MCF-7 and T47D proliferate in response to much lower
concentrations of IGF-I and IGF-II compared with ER-neg-
ative cells (e.g. MDA-MB-231) [86]. The pattern of IGFBP
expression and secretion may also be related to the ER
status of breast cancer cells [87]. For example, IGFBP-4
and IGFBP-5 mRNA concentrations are greater in ER-
positive cancer tissues compared with in ER-negative
tissue [88]. Oestrogens may also increase the level of
IGFBP proteases, leading to increased proteolysis of
IGFBPs and therefore to increased free IGFs [89].
Anti-IGF therapies and the treatment of
breast cancer
Although there are conflicting data from clinical and epi-
demiological studies concerning cancer risk and progno-
sis, the proven role of IGFs and the IGF-IR in promoting
proliferation and survival strongly implicates a role for the
IGF axis in cancer. Since IGFs can protect breast cancer
cells from cell death induced by radiation and chemothera-
peutic agents, the survival function of IGFs could provide
a mechanism of resistance to cancer therapies. To combat
this, new therapeutic approaches have been developed
using agents to reduce IGF-I levels. Both IGF-I and tumour
incidence are reduced in transgenic mice expressing a
GH antagonist exposed to the mammary gland carcino-
gen, dimethylbenz(a)anthracene [90]. Similarly, when mice
bearing mammary cancer xenografts are treated with GH-
releasing hormone antagonists, IGF-I concentrations and
mRNA are reduced and the tumour volume decreases
[91,92].
Studies such as these indicate the value of anti-IGF thera-
pies in the treatment of breast and other cancers where
the IGF axis has been implicated. Moreover, anticancer
drugs designed to inhibit other growth factor pathways
can also block IGF-mediated signals. The antiestrogen
ICI 182,780 reduces phosphorylation of the IGF-IR and
downstream effectors in a rat mammary model [93]. Addi-
tionally, transactivation of the EGF receptor by IGF-I is
blocked by an inhibitor of EGF receptor tyrosine kinase,
ZD1839, thereby inhibiting the MAPK arm of the IGF sig-
nalling pathway in mammary epithelial cells [23]. ZD1839
is currently undergoing phase III clinical trials for nonsmall
cell lung cancer, but may also be valuable in the treatment
of breast cancer.
Conclusion
In the normal mammary gland, the IGF axis is required for
development and is associated with pubertal growth, alveo-
lar growth and involution. IGFs mediate proliferation and
survival, and although it is unclear which is the predomi-
nant effect in vivo, it is probable that both are important
even though their contribution may depend on the stage of
development. The exact function of IGFBPs in the
mammary gland is far from certain, but they appear to have
a role in blocking IGF-mediated survival and inducing
apoptosis at involution.
While the present review has discussed how IGF signal
transduction is important for mammary gland develop-
ment, it is obviously just one component of a multifactorial
and complex system. In the same way, the IGF axis is
implicated as an important component in breast cancer.
Better understanding of its function and synergistic effects
with other factors may lead to the identification of new and
improved therapies.
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